Sugi Predict

Sugi Predict / Compounds / SCHEMBL1397441

SCHEMBL1397441

SCHEMBL1397441

N=C(N)c1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPH1 P17752 3/20 0.66
▸ SLC7A5 Q01650 3/20 0.62
▸ PTGS1 P23219 3/20 0.61
▸ ALPI P09923 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ XIAP P98170 1/20 0.61
▸ PRSS1 P07477 2/20 0.54
▸ PRSS2 P07478 2/20 0.54
▸ PRSS3 P35030 2/20 0.54
▸ F2 P00734 1/20 0.54
▸ PLG P00747 1/20 0.54
▸ C1S P09871 1/20 0.54
▸ HIF1A Q16665 4/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ FYN P06241 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288202 1.00 TPH1 (0.66) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL288201 1.00 TPH1 (0.66) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL1064252 1.00 TPH1 (0.66) TPH1SLC7A5PTGS1ALPIPKM
Hydrochloric Acid SCHEMBL5279289 0.98 TPH1 (0.64) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL20714851 0.86 PRSS1 (0.50) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL668746 0.85 TPH1 (0.70) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL21690013 0.85 TPH1 (0.70) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL668747 0.85 TPH1 (0.70) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL7272904 0.85 TPH1 (0.50) TPH1SLC7A5PTGS1ALPIPKM
SCHEMBL2310526 0.84 SLC7A5 (0.83) TPH1SLC7A5PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1195608-B1 Method, reagent, cartridge, and device for determining fibrinogen ROCHE DIAGNOSTICS GMBH (DE) 2005-07-20 — — EP claimed
US-6649593-B1 Amino acid derivatives including serine, leucine, valine, arginine, asparginine, methionine, glycine and phenylalanine units; S1 protease inhibition; modulation of cholesterol homeostasis in cells TULARIK INC. 2003-11-18 — — US claimed
US-6448024-B1 CLOTTING TIME IS DETERMINED BY DETECTING REDUCTION IN THE RATE OF FLOW OF BLOOD SAMPLE AND REAGENT (THROMBIN AND THROMBIN INHIBITOR) THROUGH CAPILLARY AND IS INVERSELY RELATED TO FIBRINOGEN CONCENTRATION ROCHE DIAGNOSTICS CORPORATION 2002-09-10 — — US claimed
US-20020061839-A1 Serine peptidase modulators SCHARPE SIMON LODEWIJK (BE) 2002-05-23 — — US claimed
EP-1195608-A1 Method, reagent, cartridge, and device for determining fibrinogen Roche Diagnostics GmbH (DE) 2002-04-10 — — EP claimed
JP-2002506075-A — — 2002-02-26 — — JP claimed
WO-2001027138-A2 MODULATORS OF SREBP PROCESSING TULARIK INC. (US) 2001-04-19 — — WO claimed
EP-1062222-A1 SERINE PEPTIDASE MODULATORS Fondatech Benelux N.V. (BE) 2000-12-27 — — EP claimed
WO-1999046272-A1 SERINE PEPTIDASE MODULATORS FONDATECH BENELUX N.V. (BE) 1999-09-16 — — WO claimed
WO-1993000108-A1 NOVEL INHIBITORS OF PLATELET AGGREGATION CORVAS INTERNATIONAL, INC. (US) 1993-01-07 — — WO claimed
US-20260115109-A1 STABILIZED STANNOUS COMPOSITIONS THE UNIVERSITY OF MELBOURNE (AU) 2026-04-30 — — US disclosed
US-12303548-B2 Complexes for treating sensitivity THE UNIVERSITY OF MELBOURNE (AU) 2025-05-20 — — US disclosed
WO-2025097213-A1 COMPOSITIONS AND METHODS FOR TREATING HALITOSIS THE UNIVERSITY OF MELBOURNE (AU) 2025-05-15 — — WO disclosed
EP-4545553-A2 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND ShangPharma Innovation Inc. (US) 2025-04-30 — — EP disclosed
WO-2025035186-A1 PEPTIDE CONJUGATES AND USES THEREOF MONASH UNIVERSITY (AU) 2025-02-20 — — WO disclosed
WO-1992016549-A1 PARASUBSTITUTED PHENYLALANINE DERIVATES PENTAPHARM AG (CH) 1992-10-01 — — WO disclosed
US-4977168-A Derivatives of the N α-arylsulphonylaminoacyl-p-amidinophenyl-alaninamides, and their use as medicaments SANOFI (FR) 1990-12-11 — — US disclosed
EP-0236164-B1 DERIVATIVES OF N-ALPHA-ARYLSOLFONYLAMINOACYL P-AMIDINO-PHENYLALANINAMIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THEIR INTERMEDIATES SANOFI (FR) 1990-09-12 — — EP disclosed
US-4791102-A ANTICOAGULANTS SANOFI (FR) 1988-12-13 — — US disclosed
EP-0236164-A1 Derivatives of N-alpha-arylsolfonylaminoacyl p-amidino-phenylalaninamides, process for their preparation, their use as medicaments and their intermediates SANOFI (FR) 1987-09-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115109-A1 STABILIZED STANNOUS COMPOSITIONS CHERP, FIBP, ACP3 TPH1 4647/4885SLC7A5 2280/4885PTGS1 4166/4885
US-20020061839-A1 Serine peptidase modulators FAP, CTSC, DPP4 TPH1 1989/4885SLC7A5 2460/4885PTGS1 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.